• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Century Therapeutics, Inc. - Common Stock (NQ: IPSC )

    1.080 +0.060 (+5.88%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 367,582
    Open 1.020
    Bid (Size) 1.060 (15)
    Ask (Size) 1.120 (23)
    Prev. Close 1.020
    Today's Range 0.9800 - 1.090
    52wk Range 0.9501 - 5.510
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4%
    Via Benzinga
    Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
    From Century Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -70.33%
    -70.33%
    1 Month
    -20.00%
    -20.00%
    3 Month
    -29.41%
    -29.41%
    6 Month
    -57.31%
    -57.31%
    1 Year
    -64.47%
    -64.47%

    More News

    Read More
    Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    5 Analysts Assess Century Therapeutics: What You Need To Know
    Via Benzinga
    Century Therapeutics: Q4 Earnings Insights
    Via Benzinga
    Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Robinhood To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    IPSC Stock Earnings: Century Therapeutics Beats EPS for Q2 2024
    Via InvestorPlace
    Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    IPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
    Via Benzinga
    Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.